Get the Stockscreener App
63.59
2.15%
1.34
Pre-market:
63.20
-0.39
-0.61%
Cytokinetics Inc stock is traded at $63.59, with a volume of 2.46M.
It is up +2.15% in the last 24 hours and up +15.70% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$62.25
Open:
$63.14
24h Volume:
2.46M
Relative Volume:
1.09
Market Cap:
$7.61B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-12.09
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
+9.96%
1M Performance:
+15.70%
6M Performance:
+48.44%
1Y Performance:
+24.69%
1-Day Range:
$61.69
$63.99
1-Week Range:
$57.83
$64.13
52-Week Range:
$29.31
$64.13
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
63.59 | 7.45B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
35,600 Shares in Cytokinetics, Incorporated $CYTK Purchased by Zweig DiMenna Associates LLC - MarketBeat
Nisa Investment Advisors LLC Decreases Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Key metrics from Cytokinetics Incorporated’s quarterly dataEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
How Cytokinetics Incorporated stock benefits from strong dollarJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Does Cytokinetics Incorporated qualify in momentum factor screening2025 Market Sentiment & Fast Moving Stock Trade Plans - newser.com
Key facts: Cytokinetics' stock drops 12.98% after FDA delay; lawsuit filed - TradingView
What MACD and RSI say about Cytokinetics Incorporated2025 Institutional Moves & Weekly High Potential Alerts - newser.com
Cytokinetics Incorporated recovery potential after sell off2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Pinnacle Associates Ltd. Reduces Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Why analysts remain bullish on Cytokinetics Incorporated stockMarket Movers & AI Enhanced Execution Alerts - newser.com
Is Cytokinetics Incorporated stock positioned for long term growthPortfolio Value Report & Expert Approved Momentum Ideas - newser.com
Key facts: Cytokinetics shares fall 12.98% amid FDA delay; lawsuit filed - TradingView
Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year HighHere's Why - MarketBeat
Robert Blum Sells 5,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire
Cytokinetics, Inc. Hits New 52-Week High at USD 64.13 - Markets Mojo
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
Cytokinetics Announces Upcoming Late Breaking Science Presentations on Aficamten at Major Cardiovascular Conferences - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical ... - nrtoday.com
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 - Yahoo Finance
Can Cytokinetics Incorporated (KK3A) stock test all time highs2025 Stock Rankings & Community Consensus Stock Picks - newser.com
How sentiment analysis helps forecast Cytokinetics IncorporatedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
Analyzing recovery setups for Cytokinetics Incorporated investorsJuly 2025 Market Mood & Daily Oversold Stock Bounce Ideas - newser.com
What dividend safety score for Cytokinetics Incorporated stock2025 Volume Leaders & Smart Allocation Stock Tips - newser.com
Applying Elliott Wave Theory to Cytokinetics IncorporatedJuly 2025 Catalysts & Long-Term Capital Growth Strategies - newser.com
Is Cytokinetics Incorporated stock a smart buy before Fed meetingJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
How to track smart money flows in Cytokinetics IncorporatedQuarterly Portfolio Report & AI Enhanced Execution Alerts - newser.com
Blum, Cytokinetics CEO, sells $314k in stock By Investing.com - Investing.com Australia
Cytokinetics stock hits 52-week high at 63.87 USD By Investing.com - Investing.com Canada
Investors SueWallSt as Cytokinetics, Incorporated Faces Securities Fraud Allegations - Nasdaq
Blum, Cytokinetics CEO, sells $314k in stock - Investing.com
Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative - Yahoo Finance
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ... - Caledonian Record
Cytokinetics, Incorporated Securities Fraud Class Action - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Cytokinetics stock hits 52-week high at 63.87 USD - Investing.com
Cytokinetics (CYTK) to Release Earnings on Wednesday - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by State of New Jersey Common Pension Fund D - MarketBeat
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - GlobeNewswire Inc.
CYTOKINETICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds CYTK ... - Bluefield Daily Telegraph
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Barchart.com
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - MarketScreener
Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire
Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - GlobeNewswire Inc.
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):